On February 13, 2026, the annual grand event in the Middle East’s medical laboratory field — WHX Labs Dubai — successfully concluded at the Dubai World Trade Center! The overseas team of TargetingOne Corporation, accompanied by its independently developed digital PCR technology and ultra-multiplex testing solutions, attracted partners from five continents who stopped by for discussions, writing a powerful opening chapter for its 2026 overseas market expansion!

At the WHX Labs Dubai 2026 exhibition site, the technical team from Target Biotechnology explained the fully automated process from sample loading to result analysis. Clients from various countries experienced the product’s convenience and stability firsthand. The innovative breakthroughs in digital PCR technology received high praise from industry experts. Since the exhibition began, the booth has maintained a consistently high level of popularity, with intensive visits and discussions from clients and experts in Europe, the Middle East, Southeast Asia, Africa, and South America — partners from Italy and Spain focused on local cooperation in precision oncology; clients from the UAE, Saudi Arabia, and others showed interest in implementing solutions for infectious diseases and birth defects. The Target team won unanimous recognition from global clients through professional explanations and meticulous service, laying a solid foundation for the global market layout.

In the future, Target will continue to deepen its research and development of digital PCR technology, improve its global service network, accelerate its overseas localization efforts, and work with global partners to promote the adoption of independently developed molecular diagnostic solutions in more regions, contributing to the development of global precision medicine.

● About TargetingOne ●

TargetingOne was founded in 2015 and is headquartered in Zhongguancun Science Park. As a national high-tech enterprise and a Beijing-certified “Specialized, Refined, Distinctive, and Innovative” SME, the company focuses on independent innovation in life sciences and molecular diagnostics. It boasts a high-caliber R&D team with expertise in instruments, chips, materials, reagents, and software. The company has experienced rapid growth, filing over 200 patents globally and securing more than 150 authorized patents. It consistently publishes academic papers in authoritative journals and undertakes national-level research grants.Based on its proprietary digital PCR technology, TargetingOne has obtained the first and second NMPA Class III Medical Device Registration Certificates for digital PCR systems (totaling three certificates), as well as three NMPA Class III Medical Device Registration Certificates for diagnostic reagents. Among these, its reagents for infection and solid tumor liquid biopsy were the first digital PCR diagnostic reagents to receive Class III registration in China. The company has twice been awarded the Gold Prize for Outstanding Innovative IVD Products in China, won the championship in the Zhongguancun International Frontier Technology Innovation Competition, and received the Beijing Science and Technology Award (Second Class) and the Invention Entrepreneurship Achievement Award.Additionally, its self-developed open molecular POCT integrated system and rapid qPCR testing reagents have both obtained NMPA Class III Medical Device Registration Certificates. Adhering to the philosophy of “Innovation Makes Precision Accessible,” TargetingOne is committed to developing advanced technologies that are multiplex, high-throughput, automated, contamination-resistant, and cost-effective. It aims to become a leading enterprise in life sciences and molecular diagnostics, serving the fields of life science research, precision medicine, drug development, and health management.